Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Ecallantide (Kalbitor) Peptide
Plasma kallikrein inhibitor for hereditary angioedema.
What is Ecallantide (Kalbitor)?
Ecallantide (Kalbitor) is a kallikrein inhibitor · immunology peptide studied for hereditary angioedema (acute attacks, ≥12 yrs). Below is an educational overview of Ecallantide (Kalbitor) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Kalbitor
Acute attacks of hereditary angioedema in patients 12 years and older.
A clinic-administered injection that blocks the enzyme (kallikrein) driving HAE swelling attacks.
Anaphylaxis can occur — must be administered by a healthcare provider with anaphylaxis training.
- •Headache
- •Nausea
- •Fatigue
- •Diarrhea
- •Injection-site reactions
- •Severe allergic reactions / anaphylaxis
- •Prior hypersensitivity to ecallantide
- •Settings without anaphylaxis treatment ability
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Ecallantide (Kalbitor) Mechanism of Action
60-amino-acid recombinant protein that selectively inhibits plasma kallikrein, reducing bradykinin generation during HAE attacks.
Ecallantide (Kalbitor) Research Areas & Benefits
Ecallantide (Kalbitor) Dosage & Common Research Protocols
30 mg SC (three 10 mg injections); may repeat once within 24h.
Protocols summarized for educational reference from published research. Not dosing guidance.
Ecallantide (Kalbitor) Studies & Cited Research
EDEMA trials
Improved HAE attack resolution vs placebo.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Ecallantide (Kalbitor) Side Effects & Safety Considerations
- •FDA-approved.
- •Boxed warning: anaphylaxis — administer by healthcare professional.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.